Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00698-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Yue Tu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Neoplasms, Bayes Theorem, Research Design. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, United States, University of Southern California.
Abstract (Originalsprache)
As cancer has become better understood on the molecular level with the evolution of gene sequencing techniques, considerations for individualized therapy using predictive biomarkers (those associated with a treatment’s effect) have shifted to a new level. In the last decade or so, randomized “adaptive enrichment” clinical trials have become increasingly utilized to strike a balance between enrolling all patients with a given tumor type, versus enrolling only a subpopulation whose tumors are defined by a potential predictive biomarker related to the mechanism of action of the experimental therapy. In this review article, we review recent innovative design extensions and adaptations to adaptive enrichment designs proposed during the last few years in the clinical trial methodology literature, both from Bayesian and frequentist perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Biostatistics, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, USA.
- Division of Biostatistics, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, USA. lrenfro@usc.edu.
Förderung
- NCI NIH HHS
- National Cancer Institute, United States
- University of Southern California
Zitieren
APA
Tu, Y., & Renfro, L. A. (2024). Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00698-3
Vancouver
Tu Y, Renfro LA. Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00698-3
BibTeX
@article{Tu2024,
author = {Tu, Yue and Renfro, Lindsay A},
title = {Latest Developments in “Adaptive Enrichment” Clinical Trial Designs in Oncology},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00698-3}
}
EUVIMED